glp 1 cirrhosis GLP-1 Therapies Reduce Risk of Cirrhosis, Complications of MASLD Revolutionizing MASLD treatment with GLP-1

Wegovy, a drug that is approved for weight loss, is covered by just 1% of Marketplace prescription drug plans, compared to 82% of Marketplace prescription drug plans for Ozempic, which contains the same active ingredient as Wegovy (semaglutide) but is approved only for diabetes

W., and Yang, Y

The search included terms such as small molecule GLP-1 receptor agonists, oral GLP-1 receptor agonists, Danuglipron, Orforglipron, and Aleniglipron. Additionally, information on ongoing clinical trials involving small molecule GLP-1 receptor agonists was retrieved from the ClinicalTrials.gov database using the same keywords

This maintains effectiveness while minimizing risks